Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gepefrine SCHEMBL265538 | 0.83 | TAAR1 (0.61) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Gepefrine SCHEMBL2562808 | 0.83 | TAAR1 (0.61) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Gepefrine SCHEMBL30011768 | 0.83 | TAAR1 (0.61) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| SCHEMBL19354447 | 0.83 | CHRM2 (0.53) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| SCHEMBL1044777 | 0.83 | ENPP2 (0.57) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Gepefrine SCHEMBL149774 | 0.83 | TAAR1 (0.61) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| SCHEMBL629959 | 0.83 | CHRM2 (0.53) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Gepefrine SCHEMBL2903935 | 0.81 | TAAR1 (0.59) | ENPP2DRD2DRD1TAAR1LMNA | |
| Gepefrine SCHEMBL2903938 | 0.81 | TAAR1 (0.59) | ENPP2DRD2DRD1TAAR1LMNA | |
| SCHEMBL7791226 | 0.81 | ENPP2 (0.50) | ENPP2DRD2DRD1TAAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| US-6726911-B1 | SOLVENT EXTRACT; MICROBIOCIDES; ENDOPEPTIDASE, ANGIOTENSIN CONVERTING ENZYME AND SERUM-MEDIATED-BINDING OF LIPOPOLYSACCHARIDE INHIBITORS | GANOMYCIN (DE) | 2004-04-27 | — | — | US | disclosed |
| EP-1158995-B1 | BIOLOGICALLY ACTIVE COMPOUNDS OF GANODERMA PFEIFFERI DMS 13239 | GANOMYCIN GES FUER BIOMEDIZINI (DE) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | ENPP2 830/4885DRD2 979/4885DRD1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.